RhumbLine Advisers’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-59,285
| Closed | -$1.98M | – | 4238 |
|
|
2026
Q1 | $1.98M | Buy |
59,285
+4,217
| +8% | +$165K | ﹤0.01% | 1864 |
|
|
2025
Q4 | $2.55M | Sell |
55,068
-4,792
| -8% | -$263K | ﹤0.01% | 1730 |
|
|
2025
Q3 | $4.05M | Buy |
59,860
+814
| +1% | +$60.3K | ﹤0.01% | 1549 |
|
|
2025
Q2 | $4.95M | Buy |
59,046
+22,607
| +62% | +$1.69M | ﹤0.01% | 1422 |
|
|
2025
Q1 | $2.6M | Buy |
36,439
+2,044
| +6% | +$99.5K | ﹤0.01% | 1681 |
|
|
2024
Q4 | $1.55M | Buy |
34,395
+3,624
| +12% | +$188K | ﹤0.01% | 2019 |
|
|
2024
Q3 | $1.55M | Buy |
30,771
+1,627
| +6% | +$77.9K | ﹤0.01% | 2036 |
|
|
2024
Q2 | $1.19M | Buy |
+29,144
| New | +$1.24M | ﹤0.01% | 2150 |
|
|
2021
Q2 | – | Sell |
-2,840
| Closed | -$54K | – | 3095 |
|
|
2021
Q1 | $54K | Buy |
2,840
+102
| +4% | +$3.29K | ﹤0.01% | 2973 |
|
|
2020
Q4 | $79K | Buy |
2,738
+743
| +37% | +$21.4K | ﹤0.01% | 2991 |
|
|
2020
Q3 | $75K | Sell |
1,995
-171
| -8% | -$5K | ﹤0.01% | 2919 |
|
|
2020
Q2 | $72K | Buy |
+2,166
| New | +$93.9K | ﹤0.01% | 3002 |
|
RhumbLine Advisers's SLNO Position: Q2 2026 in Review
RhumbLine Advisers sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 59,285 shares — an estimated $1.98M sold.
RhumbLine Advisers first reported a position in SLNO in Q2 2020 and held it in 12 quarters. The position peaked at $4.95M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- RhumbLine Advisers reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- RhumbLine Advisers sold 59,285 Soleno Therapeutics shares in Q2 2026, an estimated $1.98M.
- RhumbLine Advisers first reported a position in Soleno Therapeutics in Q2 2020 and held it in 12 quarters.
- RhumbLine Advisers's Soleno Therapeutics position peaked at $4.95M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.